Christopher Ian Montague Jones
Known title: DirectorCIK: 0001292762
Associated companies
Transaction History
| BDX | ▲ Buy | Grant | 1,098 | $0 | 1/27/2026 | View on chart |
| BDX | ▲ Buy | Grant | 930 | $0 | 1/28/2025 | View on chart |
| BDX | ▲ Buy | Grant | 900 | $0 | 1/23/2024 | View on chart |
| BDX | ▲ Buy | Grant | 848 | $0 | 1/24/2023 | View on chart |
| BDX | ▲ Buy | Grant | 820 | $0 | 1/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%
The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.